139183-87-2

Usage

Uses

Used in Biochemistry:
6-Aminomethyl-nicotinic acid methyl ester is used as a chemical intermediate for the synthesis of various drugs or substances with potential medical applications. Its versatility in chemical reactions allows it to be a valuable component in the development of new compounds.
Used in Pharmaceutical Manufacturing:
6-Aminomethyl-nicotinic acid methyl ester is used as a key building block in the production of pharmaceuticals. Its ability to participate in various chemical processes makes it an essential component in the synthesis of new drugs, contributing to the advancement of medicine.
Used in Research and Development:
6-Aminomethyl-nicotinic acid methyl ester is used as a research compound in the study of chemical processes and reactions. Its properties and reactivity make it a valuable tool for scientists and researchers working in the fields of biology and medicine, aiding in the discovery of new substances and applications.

InChI:InChI=1/C8H10N2O2/c1-12-8(11)6-2-3-7(4-9)10-5-6/h2-3,5H,4,9H2,1H3

Upstream product

• 22794-96-3 methyl 6-hydroxyiminomethylnicotinate 
• 49668-90-8 methyl 6-(chloromethyl)pyridine-3-carboxylate 
• 881-86-7 dimethyl 2,5-pyridine dicarboxylate 
• 56026-36-9 methyl 6-(hydroxymethyl)nicotinate 
• 951306-53-9 6-(chloromethyl)nicotinic acid methyl ester hydrochloride 
• 131803-48-0 methyl 6-bromomethylnicotinate 
• 5470-70-2 Methyl 6-methylnicotinate 
• 3222-47-7 6-methylnicotinic acid 
• 384831-56-5 6-(azidomethyl)nicotinic acid methyl ester 

Downstream Products

• 503470-75-5 6-[(3-carboxy-4-hydroxy-benzenesulfonylamino)-methyl]-nicotinic acid methyl ester 
• 773884-40-5 methyl 6-{[(3-phenylpropanoyl)amino]methyl}nicotinate 
• 1072437-74-1 6-[(3-{2-[((1R,3aS,5aR,5bR,1aR)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-9-oxo-icosahydro-cyclopenta[a]chrysene-3a-carbonyl)-amino]-ethyl}-benzoylamino)-methyl]-nicotinic acid methyl ester 
• 139183-89-4 methyl imidazo[1,5-a] pyridine-6-carboxylate 

Relevant academic research and scientific papers

Redox-Noninnocent Behavior of Tris(2-pyridylmethyl)amine Bound to a Lewis Acidic Rh(III) Ion Induced by C-H Deprotonation

Rh(III) complexes having tris(2-pyridylmethyl)amine (TPA) and its derivative as tetradentate ligands showed reversible deprotonation at a methylene moiety of the TPA ligands upon addition of a strong base as confirmed by spectroscopic measurements and X-ray crystallography. Deprotonation selectively occurred at the axial methylene moiety rather than equatorial counterparts because of the thermodynamic stability of corresponding deprotonated complexes. One-electron oxidation of the deprotonated Rh(III)-TPA complex afforded a unique TPA radical bound to the Rh(III) center by a ligand-centered oxidation. This is the first example to demonstrate emergence of the redox-noninnocent character of the TPA ligand.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

ANTIVIRAL COMPOUNDS AND USE THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design

The design, synthesis, and in vitro activities of a series of potent and selective small-molecule inhibitors of caspase-3 are described. From extended tethering, a salicylic acid fragment was identified as having binding affinity for the S4 pocket of caspase-3. X-ray crystallography and molecular modeling of the initial tethering hit resulted in the synthesis of 4, which reversibly inhibited caspase-3 with a Ki = 40 nM. Further optimization led to the identification of a series of potent and selective inhibitors with Ki values in the 20-50 nM range. One of the most potent compounds in this series, 66b, inhibited caspase-3 with a Ki = 20 nM and selectivity of 8-500-fold for caspase-3 vs a panel of seven caspases (1, 2, and 4-8). A high-resolution X-ray cocrystal structure of 4 and 66b supports the predicted binding modes of our compounds with caspase-3.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

We prepared a novel series of conformationally restricted fused imidazole derivatives 4b, 4c and 4d (possessing 4,5,6,7-tetrahydroimidazo[4,5- c]pyridine and substituted 4,5,6,7-tetrahydro-1H-benzimidazole for 4b, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine for 4c and 5,6,7,8- tetrahydroimidazo[1,5-a]pyridine for 4d as a basic amine part and (2- methoxyphenyl)aminocarbonyl group as an aromatic-carbonyl part). Their activities were then evaluated as an 5-hydroxytryptamine (5-HT3) receptor antagonist which may be useful for the treatment of irritable bowel syndrome (IBS) as well as for nausea and vomiting associated with cancer chemotherapy. The most potent compound was N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H- benzimidazole-5-carboxamide 14 in this series with an ID50 value of 0.32 μg/kg on the von Bezold-Jarisch reflex in rats and an IC50 value of 0.43 μM on the isolated colonic contraction in guinea pig, approximately ten and two times more potent than ondansetron 1, respectively. The structure- activity relationships (SAR) study suggested that the high potency of 14 may be attributed to the suitable position and direction of the N-C-N centroid in the conformationally restricted imidazole ring against the planar (2-methoxy- phenyl)aminocarbonyl part in the binding of 14 to the receptor.

TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AND SALTS THEREOF

Tetrahydroimidazopyridine derivatives which are useful for the treatment of irritable bowel syndrome are provided and can be represented by the following formula, STR1 wherein either one of X and Y is nitrogen and the other one is a radical represented by the formula = C(R 1)--; and R is a radical of the formula STR2 a radical of the formula STR3 or a radical of the formula STR4 in which R 1, R. sup.2 and R 3 are same or different and represent hydrogen or a C. sub. 1-C 6 alkyl group, and salts thereof. Pharmaceutical compositions are also provided.